Standout Papers

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic ly... 2014 2026 2018 2022 462
  1. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia (2014)
    Jennifer R. Brown, John C. Byrd et al. Blood

Citation Impact

11 from Science/Nature 65 standout
Sub-graph 1 of 21

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Cell death
2024 Standout
3 intermediate papers

Works of Dave M. Johnson being referenced

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
2014 Standout

Author Peers

Author Organic Chemistry Molecular Biology Genetics PFM Last Decade Papers Cites
Dave M. Johnson 23 203 424 287 14 735
Koen J.A. Martens 6 114 13 262
C. Schaufelberger 16 43 25 8 205
Marvin Mandelbaum 1 13 361
E. Sauvard 6 23 7 382
Evan Cohick 5 298 5 14 7 424

All Works

Loading papers...

Rankless by CCL
2026